20-Deoxy-20-fluorocamptothecin: Design and Synthesis of Camptothecin Isostere

Norio Shibata; Takehisa Ishimaru; Mai Nakamura; Takeshi Toru

doi:10.1055/s-2004-834810

LETTER

20-Deoxy-20-fluorocamptothecin: Design and Synthesis of Camptothecin Isostere

Norio Shibata*, Takehisa Ishimaru, Mai Nakamura, Takeshi Toru*
Department of Applied Chemistry, Graduate School of Engineering, Nagoya Institute of Technology, Gokiso, Showa-ku, Nagoya 466-8555, Japan
Fax: +81(52)7355442; e-Mail: nozshiba@nitech.ac.jp; e-Mail: toru@nitech.ac.jp;

Abstract

Alle Artikel dieser Rubrik

Abstract

20-Deoxy-20-fluorocamptothecin (2) has been synthesized as an isosteric analogue of camptothecin (1). The use of selectfluor or N-fluorobenzenesulfonimide for the electrophilic fluorination of 20-deoxycamptothecin (3) yields the target compound. Enantioselective fluorination of 3 was also achieved using our previously described cinchona alkaloids/selectfluor combination to provide both enantiomers of 2 with 88% ee and 81% ee, respectively.

Key words

fluorine - antitumor agent - asymmetric synthesis - camptothecin - topoisomerase I

Volltext

Referenzen

References

<A NAME="RU24904ST-1A">1a</A> Wall ME. Wani MC. Cook CE. Palmer KH. McPhail AT. Sim GA. J. Am. Chem. Soc. 1966, 88: 3888

<A NAME="RU24904ST-1B">1b</A> Wall ME. Med. Res. Rev. 1998, 18: 299

<A NAME="RU24904ST-2">2</A> For a review of the camptothecin biochemistry see: Liehr J. Giovanella BC. Verschraegen CF. Ann. N. Y. Acad. Sci. 2000, 922: 1

<A NAME="RU24904ST-3A">3a</A> Craig JT. Nicholas JR. Sidney MH. Bioorg. Med. Chem. 2004, 12: 1585

<A NAME="RU24904ST-3B">3b</A> Redinbo RR. Stewart L. Kuhn P. Champoux JJ. Hol WGJ. Science 1998, 279: 1504

<A NAME="RU24904ST-4A">4a</A> Wall ME. Wani MC. Nicholas AW. Manikumar G. Tele C. Moore L. Truesdale A. Leitner P. Besterman JM. J. Med. Chem. 1993, 36: 2689

<A NAME="RU24904ST-4B">4b</A> Wang X. Zhou X. Hecht SM. Biochemistry 1999, 38: 4374

<A NAME="RU24904ST-5A">5a</A> Jaxel C. Kohn KW. Wani MC. Wall ME. Cancer Res. 1989, 49: 1465

<A NAME="RU24904ST-5B">5b</A> Fassberg J. Stella VJ. J. Pharm. Sci. 1992, 81: 676

<A NAME="RU24904ST-6A">6a</A> Hertzberg RP. Caranfa MJ. Holden KG. Jakas DR. Gallagher G. Mattern MR. Mong SM. Bartus JO. Johnson RK. Kingsbury WD. J. Med. Chem. 1989, 32: 715

<A NAME="RU24904ST-6B">6b</A> Zhao H. Lee C. Sai P. Choe YH. Boro M. Pendri A. Guan S. Greenwald RB. J. Org. Chem. 2000, 65: 4601

<A NAME="RU24904ST-7A">7a</A> Biomedical Aspects of Fluorine Chemistry Filler R. Kobayashi Y. Kodansha/Elsevier Biomedical; Tokyo: 1982.

<A NAME="RU24904ST-7B">7b</A> Biomedical Frontiers of Fluorine Chemistry, ACS Symposium Series 639 Ojima I. McCarthy JR. Welch JT. American Chemical Society; Washington DC: 1996.

<A NAME="RU24904ST-7C">7c</A> Fusso Yakugaku Kobayashi Y. Kumadaki I. Taguchi T. Hirokawa; Tokyo: 1992.

<A NAME="RU24904ST-7D">7d</A> Welch JT. Tetrahedron 1987, 43: 3123

<A NAME="RU24904ST-7E">7e</A> Smart BE. In Organofluorine Chemistry: Principles and Commercial Applications Banks RE. Smart BE. Tatlow JC. Plenum; New York: 1994. Chap. 3. p.57

<A NAME="RU24904ST-8A">8a</A> Shibata N. Tarui T. Doi Y. Kirk KL. Angew. Chem. Int. Ed. 2001, 40: 4461

<A NAME="RU24904ST-8B">8b</A> Takeuchi Y. Tarui T. Shibata N. Org. Lett. 2000, 2: 639

<A NAME="RU24904ST-8C">8c</A> Takeuchi Y. Shiragami T. Kimura K. Suzuki E. Shibata N. Org. Lett. 1999, 1: 1571

<A NAME="RU24904ST-8D">8d</A> Shibata N. Das BK. Takeuchi Y. J. Chem. Soc., Perkin Trans. 1 2000, 4234

<A NAME="RU24904ST-8E">8e</A> Takeuchi Y. Kirihara K. Kirk KL. Shibata N. Chem. Commun. 2000, 785

<A NAME="RU24904ST-8F">8f</A> Shibata N. Das BK. Honjo H. Takeuchi Y. J. Chem. Soc., Perkin Trans. 1 2001, 1605

<A NAME="RU24904ST-8G">8g</A> Das BK. Shibata N. Takeuchi Y. J. Chem. Soc., Perkin Trans. 1 2002, 197

<A NAME="RU24904ST-9">9</A> The ability of the C-F bond to act as a hydrogen bond acceptor is a matter of considerable debate. It highly depends on the molecular structures. See: Shibata N. Das BK. Harada K. Takeuchi Y. Bando M. Synlett 2001, 1755 ; and references therein

<A NAME="RU24904ST-10A">10a</A> Nicholas AW. Wani MW. Manikumar G. Wall ME. Kohn KW. Pommier Y. J. Med. Chem. 1990, 33: 972

<A NAME="RU24904ST-10B">10b</A> Ejima A. Terasawa H. Sugimori M. Ohsuki S. Matsumoto K. Kawato Y. Yasuoka M. Tagawa H. Chem. Pharm. Bull. 1992, 40: 683

<A NAME="RU24904ST-11">11</A> Adamovics JA. Cina JA. Hutchinson CR. Phytochemistry 1979, 18: 1085

<A NAME="RU24904ST-12A">12a</A> Muniz K. Angew. Chem. Int. Ed. 2001, 40: 1653

<A NAME="RU24904ST-12B">12b</A> Hintermann L., Togni A.; Angew. Chem. Int. Ed.; 2000, 39: 4359

<A NAME="RU24904ST-12C">12c</A> Piana S. Devillers I. Togni A. Rothlisberger U. Angew. Chem. Int. Ed. 2002, 41: 979

<A NAME="RU24904ST-12D">12d</A> Togni A. Mezzetti A. Barthazy P. Becker C. Devillers I. Frantz R. Hintermann L. Perseghini M. Sanna M. Chimia 2000, 55: 801

<A NAME="RU24904ST-12E">12e</A> Cahard D. Audouard C. Plaquevent J.-C. Roques N. Org. Lett. 2000, 2: 3699

<A NAME="RU24904ST-12F">12f</A> Mohar B. Baudoux J. Plaquevent J.-C. Cahard D. Angew. Chem. Int. Ed. 2001, 40: 4214

<A NAME="RU24904ST-12G">12g</A> Kim DY. Park E. J. Org. Lett. 2002, 4: 545

<A NAME="RU24904ST-12H">12h</A> Hamashima Y. Yagi K. Takano H. Tamas L. Sodeoka M. J. Am. Chem. Soc. 2002, 124: 14530

<A NAME="RU24904ST-12I">12i</A> Ma J.-A. Cahard D. Tetrahedron: Asymmetry 2004, 15: 1007

<A NAME="RU24904ST-12J">12j</A> Ibrahim H. Togni A. Chem. Commun. 2004, 1147

<A NAME="RU24904ST-13A">13a</A> Shibata N. Suzuki E. Takeuchi Y. J. Am. Chem. Soc. 2000, 122: 10728

<A NAME="RU24904ST-13B">13b</A> Shibata N. Suzuki E. Asahi T. Shiro M. J. Am. Chem. Soc. 2001, 123: 7001

<A NAME="RU24904ST-13C">13c</A> Shibata N. Ishimaru T. Suzuki E. Kirk KL. J. Org. Chem. 2003, 68: 2494

<A NAME="RU24904ST-13D">13d</A> Shibata N. Pharmacia 2003, 39: 666

<A NAME="RU24904ST-14">14</A> Shibata N. Ishimaru T. Nagai T. Kohno J. Toru T. Synlett 2004, 1703

General Experimental Procedure: A solution of 3 (82.5 mg, 0.25 mmol) in CH₂Cl₂ (15.0 mL) was added to a stirred solution of NF-(DHQ)₂PHAL [prepared in situ from (DHQ)₂PHAL (232.0 mg, 0.30 mmol) and Selectfluor (105.5 mg, 0.30 mmol) in CH₂Cl₂ (15.0 mL) at r.t. for 30 min] at r.t. under nitrogen atmosphere. After the mixture was stirred for 1-2 d, H₂O was added to the reaction mixture and extracted with CH₂Cl₂. The organic phase was washed with 3% HCl, sat. NaHCO₃, and brine and dried over Na₂SO₄. The solvent was removed under reduced pressure to give crude product, which was purified by silica gel column chromatography eluting with 1% MeOH in CHCl₃ to give 2 (85.5 mg, 98%) as yellow powders. The ee was determined to be 81% by HPLC analysis (at a wavelength of 224 nm) using a CHIRALCEL OD-H (250 mm, 4.6 mm) eluting with EtOH at a flow rate of 1.0 mL/min. t _R [20 (R)-FluoroCPT (2)] = 11.5 min, t _R [20(S)-FluoroCPT (2)] = 14.5 min. ¹H NMR (270 MHz, CDCl₃): δ = 8.43 (s, 1 H), 8.25 (d, J = 8.6 Hz, 1 H), 7.96 (d, J = 7.6 Hz, 1 H), 7.86 (t, J = 7.6 Hz, 1 H), 7.69 (t, J = 7.6 Hz, 1 H), 7.55 (s, 1 H), 5.51 (AB q, J = 16.5 Hz, 2 H, Δν = 106.4 Hz), 5.33 (s, 2 H), 2.14 (dq, J = 21.3, 7.3 Hz, 2 H), 1.13 (t, J = 7.3 Hz, 3 H). ¹⁹F NMR (254 MHz, CDCl₃): δ = -163.16 (t, J = 21.3 Hz). ESI-MS: m/z = 350 [M⁺]; found: 351 [M⁺ + 1]. IR (KBr): 1765, 1659, 1609 cm^-1. Anal. Calcd for C₂₀H₁₅FN₂O₃: C, 68.57; H, 4.32; N, 8.00. Found: C, 68.68; H, 4.23; N, 7.97.
20(S)-FluoroCPT (2, 92% ee, recrystallized from MeOH-CHCl₃): mp 256-258 °C (MeOH-CHCl₃). [a]_D ²⁶ +71.6 (c 0.153, CHCl₃). CD (c 0.054 mmol dm^-3, MeOH, 26 °C) Δε/dm³ mol^-1 cm^-1 (λ/nm): 0 (402.0), -1.24 (357.0), 0 (312.3), +0.46 (304.2), +0.17 (290.2), +16.2 (231.6), +5.12 (221.0).
20(R)-FluoroCPT (2, 98% ee, recrystallized from MeOH-CHCl₃): mp 257-259 °C (MeOH-CHCl₃). [a]_D ²⁶ -75.8 (c 0.172, CHCl₃). CD (c 0.054 mmol dm^-3, MeOH, 26 °C) Δε/dm³ mol^-1 cm^-1 (λ/nm) +0.02 (402.0), +1.36 (354.2), 0 (311.9), -0.48 (302.8), -0.13 (287.8), -17.4 (231.8), -8.47 (221.0).
CPT 1: CD (c 0.054 mmol dm^-3, MeOH, 26 °C) Δε/dm³ mol^-1 cm^-1 (λ/nm) -0.06 (402.0), -1.88 (360.8), 0 (309.3), +0.32 (304.2), 0 (291.3), -0.08 (288.8), 0 (284.5), +18.2 (232.8), +6.10 (221.0).

<A NAME="RU24904ST-16A">16a</A> Lin L. Shen J. Zhou T. Shen C. Ke M. Huaxue Xuebao 1989, 47 (5): 506

<A NAME="RU24904ST-16B">16b</A> Kitajima M. Nakamaura M. Takayama H. Saito K. Stockigt J. Amii N. Tetrahedron Lett. 1997, 38: 8997

<A NAME="RU24904ST-17A">17a</A> Jennings JP. Klyne W. Scopes PM. J. Chem. Soc. 1965, 7211

<A NAME="RU24904ST-17B">17b</A> Lowe G. Potter BVL. J. Chem. Soc., Perkin Trans. 1 1980, 2029

<A NAME="RU24904ST-17C">17c</A> Kirk DN. Tetrahedron 1986, 42: 777

<A NAME="RU24904ST-17D">17d</A> Takeuchi Y. Suzuki T. Satoh A. Shiragami T. Shibata N. J. Org. Chem. 1999, 64: 5708

<A NAME="RU24904ST-18">18</A> Mazzinia S. Belluccia MC. Dallavallea S. Fraternalib F. Mondelli R. Org. Biomol. Chem. 2004, 2 (4): 505

In initial cytotoxicity study, both 20(S)- and 20(R)-fluoroCPT (2) were evaluated on three human cancer cell lines (KB, A549 and HT-29) and they appeared to be less active than CPT (1). Further biological study using pure enantiomer of 2 is now under considerations.